Kymera Therapeutics KYMR CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kymera Therapeutics's capex?
- Kymera Therapeutics (KYMR) reported capex of $434K in Q1 2026.
- How has Kymera Therapeutics's capex changed year-over-year?
- Kymera Therapeutics's capex decreased by 7.1% year-over-year, from $467K to $434K.
- What is the long-term trend for Kymera Therapeutics's capex?
- Over 4 years (2021 to 2025), Kymera Therapeutics's capex has grown at a -2.4% compound annual growth rate (CAGR), from $1.6M to $1.45M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.